Couldn't you literally say this about every biotech stock before their first approval? HIV hit the primary endpoint with stat sig and have attempted to address all of the issues the FDA had with the first BLA. They've revised their CD12 trial to include more patients and more doses, mTNBC phase 2 results look promising, LH phase 2 results look promising, and we'll get NASH phase 2 results at some point before year end. Those are all reasons to think something may change. Doesn't mean they will...but they could.